Evidence map›Paper›PMID 36541926›Full record

ArticleThe Journal of pathology2023

Advancing gastric cancer precision medicine with novel genomic screens

Nicole B Halmai, Luis G Carvajal-Carmona

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Nicole B HalmaiGenome Center, University of California at Davis, Davis, CA, USA.ORCID 0000-0002-0790-6548
Luis G Carvajal-CarmonaGenome Center, University of California at Davis, Davis, CA, USA.ORCID 0000-0001-7129-2918

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9M
University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health DisparitiesU54CA233306 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CARVAJAL CARMONA, LUIS GUILLERMO, CHEN, MOON SHAO-CHUANG · 2018 to 2022
$6.8M
Genetic studies of homologous recombination deficiency in hispanic gastric cancerR01CA223978 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CARVAJAL CARMONA, LUIS GUILLERMO · 2018 to 2022
$3.0M
Dissecting gastric cancer clonality with genomic analyses and patient xenograftsR21CA199631 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CARVAJAL CARMONA, LUIS GUILLERMO · 2016 to 2017
$376k
NCI NIH HHS P30CA093373NCI NIH HHS R01CA223978NCI NIH HHS R21CA199631NCI NIH HHS U54CA233306NCI NIH HHS U54CA233306-1S2
6 · The paper itself

Abstract

A recent study published in The Journal of Pathology used an shRNA library targeting all known human genes involved in metabolism to identify genes important for gastric cancer. The screen identified aspartyl-tRNA synthetase (DARS) as a potential drug target, and patients whose tumors had high DARS levels had a worse prognosis, particularly among diffuse-type gastric cancer. These findings identify a potential therapeutic target for precision medicine of gastric cancer patients, and may be useful for further investigations to discover additional interacting targets. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Indexed as

Stomach NeoplasmsGenomeGenomicsHumansPrecision MedicineUnited Kingdomaspartyl-tRNA synthetasegastric cancermetabolismsynthetic lethality

Identifiers

PMID36541926
PMCPMC9998346

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.